Blog

• Wondering if Tokyo GasLtd is fairly priced, or if the market is missing something? You’re in the right place for a deeper dive into its true value.

• Shares have been on a strong run lately, with an 18.9% jump over the past month and an impressive 44.4% rally so far this year. This hints at changing growth expectations and risk appetite.

• Recent news has highlighted the company’s strategic investments in renewable energy and its push towards decarbonization. Both factors are helping drive renewed investor interest. These developments have provided fresh context for the stock’s upward momentum as Tokyo GasLtd adapts to evolving energy trends in Japan.

• But does the current price reflect the fundamentals? Based on a valuation score of 2 out of 6, there is more to uncover. Not just by the numbers, but by exploring smarter ways to value stocks. Stay tuned for a practical walkthrough and a different approach later in the article.

Tokyo GasLtd scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

A Discounted Cash Flow (DCF) model estimates a company’s intrinsic value by projecting its future cash flows and discounting them back to today’s value. This approach provides a grounded sense of what the business is really worth, based on its ability to generate cash in the years ahead.

For Tokyo GasLtd, the most recent Free Cash Flow reported is approximately ¥146.3 billion. Analyst estimates predict some fluctuation over the next decade, with projected Free Cash Flow for the year ending March 2030 around ¥78.4 billion. It is important to note that while detailed analyst forecasts typically only reach five years, later projections are extrapolated based on recent trends.

According to the DCF model, this steady outlook leads to an estimated intrinsic value of ¥5,370 per share. Currently, the stock is trading at a level that is 17.9% above this calculated fair value. This suggests that Tokyo GasLtd is trading at a noticeable premium relative to its underlying cash flow generation potential.

Result: OVERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Tokyo GasLtd may be overvalued by 17.9%. Discover 913 undervalued stocks or create your own screener to find better value opportunities.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Tokyo GasLtd.

The Price-to-Earnings (PE) ratio is a widely used valuation metric for profitable companies like Tokyo GasLtd because it ties a company’s share price directly to its current ability to generate profits. For investors, the PE ratio provides a clear picture of how much the market is willing to pay for each yen of earnings, making it a practical gauge for relative valuation.

Growth expectations and perceived risks play a big role in determining what is considered a “normal” or “fair” PE ratio. Companies expected to grow faster or those operating in lower-risk environments may justify higher PE multiples, while slower growth or higher risk can bring the ratio down below sector norms.

At present, Tokyo GasLtd is trading at a PE ratio of 11.6x. This is below both the industry average for Gas Utilities of 14.4x and the peer group average of 16.3x, suggesting the market is more cautious than the broader sector or Tokyo GasLtd’s direct competitors.

Simply Wall St’s proprietary “Fair Ratio” offers a more tailored benchmark, blending factors such as Tokyo GasLtd’s profit margins, growth profile, market cap, risk exposures, and its industry context. This customized ratio, 7.4x for Tokyo GasLtd, provides a deeper, company-specific gauge of value than standard industry averages or peer comparisons, which can miss nuance around a company’s individual prospects and risks.

Since the market PE ratio of 11.6x is notably higher than the Fair Ratio of 7.4x, Tokyo GasLtd appears overvalued by this measure, even though it seems less expensive than other peers and its industry on traditional multiples.

Result: OVERVALUED

PE ratios tell one story, but what if the real opportunity lies elsewhere? Discover 1437 companies where insiders are betting big on explosive growth.

Earlier we mentioned that there is an even better way to understand valuation, so let’s introduce you to Narratives. A Narrative is a simple, approachable way for investors to describe their perspective on a company like Tokyo GasLtd, providing the story behind their numbers by sharing assumptions about fair value, future revenue, earnings, and margins.

Narratives connect each investor’s story to a specific financial forecast, turning personal insights into a calculated fair value and actionable investment view.

Using Simply Wall St’s Community page, millions of investors can easily access, create, and compare Narratives, making it simple to see how different viewpoints influence when to buy or sell, especially by comparing each Narrative’s Fair Value to the current Price.

Narratives are dynamic and instantly update with new information such as news or earnings releases, so your valuation story is always current.

For example, among Tokyo GasLtd Narratives, some investors are optimistic and estimate a much higher future fair value based on strong growth in renewables, while others take a more cautious stance and see a much lower fair value.

Do you think there’s more to the story for Tokyo GasLtd? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include 9531.T.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

• In late November 2025, Goldman Sachs completed a series of fixed-income offerings totaling over US$120 million in senior and subordinated notes with varied maturities and fixed coupons, while also securing exclusive negotiation rights to purchase Restaurant Brands International’s Japan operations, valued at around ¥70 billion (US$452 million).

• The combination of successful bond issuances and expansion opportunities reflect Goldman Sachs’ continued focus on strengthening its capital base and diversifying its business activities.

• We’ll examine how Goldman Sachs’ strong performance in investment banking and recent capital market activities shape the company’s investment narrative.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 25 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

To be a shareholder in Goldman Sachs Group, you need to believe in the firm’s ability to drive long-term growth through its core strengths in investment banking, asset management, and capital markets innovation. The recent series of fixed-income offerings and the exclusive negotiation rights for Restaurant Brands International’s Japan operations highlight Goldman’s focus on capital strength and business diversification. These actions have no material impact on the company’s main short-term catalyst, which remains robust M&A activity, or on its largest current risk: regulatory uncertainty and pending changes to capital requirements.

Among recent announcements, the acquisition of exclusive rights to negotiate the purchase of RBI’s Japanese operations is particularly relevant. This move underscores Goldman’s pursuit of high-profile deals and international expansion, supporting its ongoing strategy of seeking new revenue streams beyond its traditional segments and reinforcing the investment banking backlog that continues to fuel advisory revenues.

But contrasting the company’s expansion efforts, investors should also be aware of upcoming regulatory challenges and potential increases in compliance costs, because…

Read the full narrative on Goldman Sachs Group (it’s free!)

Goldman Sachs Group’s outlook anticipates $61.4 billion in revenue and $17.0 billion in earnings by 2028. This is based on a projected annual revenue growth rate of 3.9% and a $2.3 billion increase in earnings from the current $14.7 billion.

Uncover how Goldman Sachs Group’s forecasts yield a $802.53 fair value, a 3% downside to its current price.

Nine private investors from the Simply Wall St Community set fair values for Goldman Sachs between US$498,314 and US$815,000, highlighting widely differing views. These contrasting opinions come as new regulatory risks could reshape the company’s future profitability, so consider several viewpoints before deciding.

Explore 9 other fair value estimates on Goldman Sachs Group – why the stock might be worth 40% less than the current price!

Disagree with existing narratives? Create your own in under 3 minutes – extraordinary investment returns rarely come from following the herd.

• A great starting point for your Goldman Sachs Group research is our analysis highlighting 5 key rewards that could impact your investment decision.

• Our free Goldman Sachs Group research report provides a comprehensive fundamental analysis summarized in a single visual – the Snowflake – making it easy to evaluate Goldman Sachs Group’s overall financial health at a glance.

Our top stock finds are flying under the radar-for now. Get in early:

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include GS.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Research and Real-world Outcomes Underscore Transpara Breast AI’s Impact on Cancer Detection and Breast Imaging Workflow

CHICAGO, Nov. 30, 2025 /PRNewswire/ — ScreenPoint Medical is showcasing the industry-leading Transpara Breast AI suite, an integrated set of solutions that includes Detection, Density, and Temporal Comparison at the 111^th Annual Radiological Society of North America (RSNA) Annual Meeting, November 30-December 4, 2025 (South Hall #4719). The most clinically validated Breast AI on the market, Transpara Breast AI is built for enterprise workflows to provide radiologists with a ‘second pair’ of eyes to help detect cancer earlier, reduce radiologist workload, and improve program performance.

2025 has been a pivotal year for ScreenPoint Medical. Surpassing 11 million mammograms processed, Transpara Breast AI is deployed in over 30 countries at leading healthcare providers and has been selected by 40% of the 2025 US News and World Report’s Top 20 Best Hospitals Honor Roll recipients.

Additionally, Transpara Breast AI has been chosen in to be part of the only randomized controlled trials (RCTs) in the field of Breast AI: the MASAI RCT in Sweden and the upcoming $16mil PRISM RCT in the United States, which will commence in early 2026 and is spearheaded by researchers at UCLA and UC Davis. Results from MASAI published earlier this year found a 29% increase in cancer detection and a 44% decrease in screen-reading workload when using Transpara Detection compared to the standard of care.

Risk assessment is also a key theme at RSNA 2025: Transpara Risk, an image-based 5-year risk model for breast cancer,  and Transpara Detection are the subjects of a powerful new study, “Added Value of Breast Cancer Risk Prediction Versus Detection Over a Two-year Time Period with Mammography” (S5-SSBR02-4, Sunday, November 30, 2:30 PM, S406A). This research shows the added value of risk prediction for precision care, with Transpara solutions outperforming both RSNA CAD and Mirai. AI-based risk analysis supports ScreenPoint Medical’s commitment to women worldwide by powering personalized prevention pathways and enabling earlier diagnosis for less invasive treatment. Transpara Risk is approved for investigational use only.

In addition to Sunday’s session, the clinical and workflow benefits of Transpara Breast AI are the subject of notable presentations and posters throughout the week at RSNA:

• The study, “Comparing Four Commercial AI Algorithms for Standalone Breast Cancer Detection on Digital Breast Tomosynthesis in a Dutch Population-based Screening Cohort” (T3-SSBR05-6, Tuesday, December 2, 9:30 AM, S406A) is the first study to compare commercial AI algorithms for screening DBT on the same large dataset. The results showed significant differences in performance between some of the four commercial AI algorithms with Transpara Detection outperforming the competition. 
• The poster, “Potential of Artificial Intelligence to Detect Interval Breast Cancers” (M5A-SPBR, Monday, December 1, 12:15 PM, Learning Center) suggests that Transpara Detection may have facilitated earlier detection of 38% of interval breast cancers, especially those missed or underestimated by radiologists. Research conducted at Johns Hopkins Medicine.
• The study, “Use of Multiple Prior Exams Improves Specificity of an AI System for Breast Cancer Detection in a Retrospective Multi-site Validation” (T3-SSBR05, Tuesday, December 2, 9:30 AM, S406A) finds that Transpara Breast AI achieves a higher specificity when using prior exams for analysis.
• The poster, “Real-World Performance of an FDA-approved Artificial Intelligence Tool for Screening Mammography” (W5B-SPBR-3, Wednesday, December 3, 12:45 PM, Learning Center) shows early positive results of clinical adoption into a busy screening mammography practice. Transpara Detection demonstrated strong performance in stratifying cancer risk and supporting recall decisions. Research conducted at Johns Hopkins Medicine.
• The study, “AI Pre-reading of Digital Breast Tomosynthesis: A Multi-site Validation of a Novel Imaging Biomarker for Confident Identification of Normal DBT Examinations” (R1-SSBR10, Thursday, December 4, 8:00 AM, S406A), showed that a novel AI-driven imaging biomarker for pre-reading of DBT can confidently identify approximately one-third of normal DBT screening exams with a negative predictive value nearing 100%. This may enable pre-reading in screening, potentially allowing radiologists to accelerate the reading of this group of DBT exams, safely improving radiologist efficiency and reducing workload.

“We believe that research drives real-world results. The groundbreaking research presented at RSNA 2025 this week as well as our ongoing research across breast imaging RCTs support the reality that Transpara Breast AI is elevating the standard of care” said Pieter Kroese, CEO of ScreenPoint Medical. “Our partners, our performance, and our product are the reasons healthcare leaders consistently choose Transpara Breast AI. We look forward to fruitful dialogue and forward momentum at radiology’s leading conference.”

To discover more about the leading Breast AI solutions on the market, visit Booth #4719 (South Hall) at RSNA 2025 or schedule an online product overview after the show at https://screenpoint-medical.com

About ScreenPoint Medical 

In the fight against breast cancer, every image is an opportunity: to unlock insight, to uncover risk, to embody health, to empower life. We build AI-powered technology for every step of the breast imaging continuum, improving consistency, reducing uncertainty, enhancing patient experience, and translating opportunity into tangible outcomes.

Proven through research, driven by innovation, and tailor-made for those seeking to lead in breast health, ScreenPoint’s Transpara Breast AI is trusted by radiologists and women across the globe. We are Breast AI. Learn more at https://screenpoint-medical.com

SOURCE ScreenPoint Medical